| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
|
Eur J Cancer
|
2009
|
77.71
|
|
2
|
Breast cancer in China.
|
Lancet Oncol
|
2014
|
2.90
|
|
3
|
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
|
Clin Cancer Res
|
2001
|
2.64
|
|
4
|
Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study.
|
Am J Epidemiol
|
2009
|
2.14
|
|
5
|
Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.
|
J Clin Oncol
|
2015
|
1.85
|
|
6
|
Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer.
|
Int J Colorectal Dis
|
2009
|
1.46
|
|
7
|
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
|
Lancet Oncol
|
2015
|
1.41
|
|
8
|
Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice.
|
Br J Clin Pharmacol
|
2013
|
1.19
|
|
9
|
Commentary: Oncologic drugs in patients with organ dysfunction: a summary.
|
Oncologist
|
2007
|
1.10
|
|
10
|
Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer.
|
J Clin Oncol
|
1995
|
1.05
|
|
11
|
Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys.
|
Clin Cancer Res
|
2011
|
1.05
|
|
12
|
Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer.
|
Breast Cancer Res Treat
|
2010
|
1.01
|
|
13
|
CD133, Trop-2 and alpha2beta1 integrin surface receptors as markers of putative human prostate cancer stem cells.
|
Am J Transl Res
|
2010
|
0.89
|
|
14
|
CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates.
|
Clin Cancer Res
|
2009
|
0.89
|
|
15
|
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).
|
Oncotarget
|
2015
|
0.89
|
|
16
|
Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan).
|
Clin Cancer Res
|
2015
|
0.82
|
|
17
|
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.
|
Bioconjug Chem
|
2015
|
0.81
|
|
18
|
Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer.
|
Breast Cancer (Auckl)
|
2016
|
0.75
|
|
19
|
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.
|
Cancer
|
2017
|
0.75
|
|
20
|
Management of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment options.
|
Cancer Manag Res
|
2015
|
0.75
|